COVID-19 vaccine nationalism could cost world up to $1.2 trillion: New RAND Europe study

Study shows global access to COVID-19 vaccines is best for world's health and wealth
28-Oct-2020 12:45 PM EDT, by RAND Corporation

Newswise — Nationalistic behaviour by governments may exclude some countries from gaining access to COVID-19 vaccines and cost the global economy up to $1.2 trillion a year in GDP, according to a new study from the not-for-profit research organisation RAND Europe.

If countries demonstrate 'vaccine nationalism' - prioritising their own citizens and insisting on first access to vaccines by signing deals directly with pharmaceutical companies and hoarding supplies - this could mean that, by initially immunising only their own populations, they incur economic penalties for themselves as well as the wider global population.

The study's macroeconomic analysis shows that, as long as the virus is not under control in all regions of the world, there will continue to be a global cost associated with COVID-19 and its prolonged negative impact on certain economic sectors.

Even if only the lowest-income countries were denied equal access to a vaccine and all other countries managed to immunise their populations against the virus, it could still cost the global economy $153 billion a year in GDP terms. The US would lose $16 billion a year, the EU $40 billion a year, the UK $5 billion a year, China $14 billion a year, and other high-income countries collectively $39 billion a year.

The study also notes that there are economic incentives to providing global access to vaccines. Based on previous estimates, it would cost $25 billion to supply lower-income countries with vaccines. The US, UK, EU and other high-income countries combined could lose about $119 billion a year if the poorest countries are denied a supply. If these high-income countries paid for the supply of vaccines, there could be a benefit-to-cost ratio of 4.8 to 1. For every $1 spent, high-income countries would get back about $4.8.

"The study shows that a globally coordinated multilateral effort to fight the pandemic is key, not only from a public health perspective but also an economic one. If too many countries follow a 'vaccine nationalism' approach regarding the development, production and distribution of COVID-19 vaccines, it could seriously hurt globally equitable access for those most at risk," said Marco Hafner, the study's lead author and senior economist at RAND Europe. "Our findings suggest that there are real economic incentives for the higher income countries to drive vaccine development and distribution to ensure that the rest of the world has access to vaccines as soon as possible."

The authors reached their conclusions by comparing the impact on global GDP of physical distancing and changes in consumer behaviour in highly contact-intensive service sectors - such as hospitality, retail and healthcare - to that of a hypothetical baseline scenario where every country manages to sufficiently immunise its population and physical distancing rules and regulations can be eased.

The study also examined the economic costs if no vaccine is developed against the disease. According to the analysis, the global economic cost associated with COVID-19 could be $3.4 trillion a year in lost GDP, compared to a scenario in which all countries can sufficiently inoculate their population.

Hafner said: "Given the substantial economic loss caused by COVID-19, investing heavily in the research and development and upscaling of vaccine manufacturing is key to finding a way out of the pandemic."

Beyond the economic implications, the global competition for vaccines may lead to preventable deaths if vulnerable people in certain countries receive the vaccine after those at low risk in other countries. The study recommends that enforceable frameworks for vaccine development and distribution be established, ensuring equitable access across the world and supporting a programme of inoculation over time.

###

 

Funding for this research was made possible by the independent research and development provisions of RAND's contracts for the operation of its US Department of Defense federally funded research and development centers.

Other authors of the report, "COVID-19 and the cost of vaccine nationalism", are Erez Yerushalmi, Clement Fays, Eliane Dufresne and Christian van Stolk.

Notes to Editors:

  • To request a copy of the embargoed report or arrange an interview with one of the researchers on the project, contact Cat McShane or Lynne Saylor on europeanmedia@randeurope.org or +44 (0) 1223 353 329  
  • The RAND Corporation is a research organisation that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is non-profit, non-partisan and committed to the public interest.  
  • RAND Europe, an affiliate of the RAND Corporation, is a not-for-profit research organisation whose mission is to help improve policy and decision making through research and analysis http://www.randeurope.org




Filters close

Showing results

110 of 4154
Newswise:Video Embedded covid-19-update-surge-preparedness-vaccine-distribution
VIDEO
Released: 30-Nov-2020 2:20 PM EST
COVID-19 Update: Surge Preparedness, Vaccine Distribution
Cedars-Sinai

With the novel coronavirus spreading across the U.S. at a record pace, Cedars-Sinai has been seeing an increase in COVID-19 patients at its hospitals and through its network of physicians. But the health system's leaders say Cedars-Sinai is prepared.

Released: 30-Nov-2020 1:20 PM EST
Rethink COVID-19 infection control to keep primary schools open this winter, governments urged
BMJ

An urgent rethink of infection control policies to keep COVID-19 infection at bay in schools is needed if primary schools are to be kept open this winter, and the knock-on effects on their families avoided, argue children's infectious disease specialists in a viewpoint, published online in the Archives of Disease in Childhood.

Newswise: Hackensack University Medical Center Urologists Continue to Provide State-of-the-Art Care During COVID-19
Released: 30-Nov-2020 12:45 PM EST
Hackensack University Medical Center Urologists Continue to Provide State-of-the-Art Care During COVID-19
Hackensack Meridian Health

Don’t Delay Your Care – Our dnhanced pandemic safety precautions prioritize patient health and allow providers to deliver outstanding in-office, telehealth and surgical care

Released: 30-Nov-2020 12:10 PM EST
Struggles of care home staff during COVID-19 first wave revealed in Whatsapp messages
University of Leeds

Analysis of social media messages between care home staff on the coronavirus front line reveal their growing concerns over how to manage in the face of the virus.

Released: 30-Nov-2020 11:30 AM EST
More than one-third of children with COVID-19 show no symptoms: study
University of Alberta Faculty of Medicine & Dentistry

More than one-third of kids who have COVID-19 are asymptomatic, according to a University of Alberta study that suggests youngsters diagnosed with the disease may represent just a fraction of those infected.

Newswise: Promising lab results in quest to find naturally occurring anti-COVID therapies
24-Nov-2020 5:35 PM EST
Promising lab results in quest to find naturally occurring anti-COVID therapies
University of Alabama Huntsville

So far, 35 of 125 naturally occurring compounds identified computationally at The University of Alabama in Huntsville (UAH) to have potential against COVID-19 have shown efficacy in ongoing first-batch testing at the University of Tennessee Health Science Center’s Regional Biocontainment Laboratory (UTHSC RBL) that’s the next step in the process to becoming a drug.

Released: 30-Nov-2020 9:45 AM EST
Rutgers Leading Coronavirus Therapeutic Clinical Trial
Rutgers University-New Brunswick

Rutgers is leading a clinical trial assessing the efficacy of a three-drug combination in treating people infected with SARS-CoV-2 and asymptomatic or mildly symptomatic.

access_time Embargo lifts in 2 days
Embargo will expire: 1-Dec-2020 11:00 AM EST Released to reporters: 30-Nov-2020 8:40 AM EST

A reporter's PressPass is required to access this story until the embargo expires on 1-Dec-2020 11:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: COVID-19 Peer Hub combats vaccine avoidance amid pandemic
Released: 27-Nov-2020 8:05 AM EST
COVID-19 Peer Hub combats vaccine avoidance amid pandemic
University of South Australia

UniSA researchers are evaluating a new vaccination education initiative – the COVID-19 Peer Hub – to help immunisation and public health professionals to tackle the emerging dangers of vaccine hesitancy amid the pandemic.

Newswise: Long-Term Impacts of COVID-19: Your Mental Health
Released: 25-Nov-2020 2:15 PM EST
Long-Term Impacts of COVID-19: Your Mental Health
Cedars-Sinai

The COVID-19 pandemic has shaped more than half a year of our lives, canceling plans, upending livelihoods and causing feelings of grief, stress and anxiety. And Cedars-Sinai mental health experts say the pandemic could be shaping our mental health well into the future.


Showing results

110 of 4154

close
1.52035